It is estimated that approximately 40% to 50% of patients with hormone receptor-positive/HER2− breast cancer have aberrant activation of PIK3CA (encoding the p110α isoform of PI3K) (11, 12), which is closely correlated with ET resistance. Here, NR4A1 is linked to breast cancer.